ArriVent BioPharma, Inc. Common Stock (AVBP) Earnings History
Annual and quarterly earnings data from 2021 to 2025
Loading earnings history...
AVBP EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AVBP Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export AVBP earnings history in CSV or JSON format
Free sign-in required to download data
ArriVent BioPharma, Inc. Common Stock (AVBP) Earnings Overview
As of May 8, 2026, ArriVent BioPharma, Inc. Common Stock (AVBP) reported trailing twelve-month net income of -$166M, reflecting -68.8% year-over-year growth. The company earned $-4.32 per diluted share over the past four quarters.
Looking at the long-term picture, AVBP's historical earnings data spans multiple years. The company achieved its highest annual net income of -$37M in fiscal 2022.
ArriVent BioPharma, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), TPVG (-$12M net income, 50.6% margin), KYMR (-$315M net income, -794.4% margin), AVBP has comparable earnings metrics. Compare AVBP vs RCUS →
AVBP Earnings vs Peers
Earnings metrics vs comparable public companies
AVBP Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$166M | -106.6% | $0 | $-4.32 | - | - |
| 2024 | -$80M | -16.1% | -$94M | $-2.56 | - | - |
| 2023 | -$69M | -87.9% | -$75M | $-2.17 | - | - |
| 2022 | -$37M | +28.5% | -$37M | $-1.10 | - | - |
| 2021 | -$52M | - | -$9M | $-40.44 | - | - |
See AVBP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVBP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVBP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAVBP — Frequently Asked Questions
Quick answers to the most common questions about buying AVBP stock.
Is AVBP growing earnings?
AVBP EPS fell to $-4.32, with earnings declining -68.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-166M.
What are AVBP's profit margins?
ArriVent BioPharma, Inc. Common Stock net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are AVBP's earnings?
AVBP earnings data spans 2021-2025. The declining earnings trend is -68.8% YoY. Historical data enables comparison across business cycles.